Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exosome Diagnostics Raises $27 Million in Series B Financing

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Proceeds will be used to advance development of the company's proprietary platform technology and commercial programs.

Exosome Diagnostics announce the initial close of its Series B financing round with the raising of $27 million. 

Key Points:

  • Co-leading the financing were new investors QIAGEN and Arcus Ventures
  • New participating investors included Tiger Partners L.P. (an investment vehicle managed by Julian H. Robertson, Jr.), CD Ventures and Monashee Capital
  • Existing participating investors included NGN Capital and Forbion Capital Partners
  • Steven Soignet, M.D., general partner at Arcus Ventures and former faculty member at Memorial Sloan Kettering Cancer Center, to join Exosome's Board of Directors
  • Use of proceeds will include:

1. Launch of the first clinical diagnostic product in the U.S. planned for 2014; EXO106 is a diagnostic test using a non-invasive urine sample which could potentially reduce the number of unnecessary prostate biopsies in patients with an elevated PSA

2. Development under an expanded collaboration with QIAGEN of a blood-based diagnostic test measuring an actionable mutation in non-small cell lung cancer; EXO501 is expected to provide repeated, non-invasive assessment of tumor mutation status

3. Development of a blood-based, multi-gene clinically actionable biomarker panel for use in oncology applications; EXO1000 expected to measure key gene mutations and gene expression levels routinely used in oncology

4. Global launch of exoRNeasy® research kits for RNA extraction from blood serum/plasma targeted for Q2 2014; exoRNeasy® will carry the QIAGEN and Exosome Diagnostics brand names

5. Continued research and development of the Exosome Diagnostics proprietary technology platform

  • Leerink Swann served as financial advisor and placement agent to Exosome Diagnostics in connection with the Series B private placement

"Our proprietary fluid-based technology platform represents a significant advance in delivering molecular diagnostic information without the patient needing to undergo an invasive tissue biopsy. 2014 will be a transformative year as we bring our first commercialized products to market," James McCullough, chief executive officer of Exosome Diagnostics

"Exosome Diagnostics technology will advance cancer care by allowing the collection of longitudinal molecular information that can potentially improve the use of cancer therapeutics and may serve as a method to diagnose and assess for recurrence of disease," Steven Soignet, M.D., general partner of Arcus Ventures.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!